(Q34096881)

English

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

6

object named as

Marc Ladanyi

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Valerie W Rusch

7

object named as

Valerie Rusch

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Alex J Rai

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Raja M Flores

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Anu Mathew

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Rita Gonzalez-Espinoza

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Matthew Bott

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Martin Fleisher

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

1 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Clinical Chemistry and Laboratory Medicine

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

271-278

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

The European mesothelioma epidemic

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Positron emission tomography predicts survival in malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Mesothelin variant 1 is released from tumor cells as a diagnostic marker.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Malignant mesothelioma 2008.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Molecular cloning and expression of megakaryocyte potentiating factor cDNA

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Tumorigenic properties of alternative osteopontin isoforms in mesothelioma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Biomarkers for mesothelioma.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

MESOMARK: a potential test for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Mesothelin-family proteins and diagnosis of mesothelioma

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.066

21 January 2018

Identifiers

10.1515/CCLM.2010.066

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34096881&oldid=2033418594"